Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021

NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section … [Read more…]

Cohesity Research Reveals U.S. Consumers’ Distrust of Corporate Ransom Payouts

Over Half Say Paying Ransom Encourages More Crime and Want Their Data Better Protected SAN JOSE, Calif.–(BUSINESS WIRE)–New research from Cohesity, a leader in next-gen data management, reveals how Americans feel about corporations giving in to the demands of ransomware attackers – and the bottom line is that Americans don’t feel good about it. This … [Read more…]

Medchart Named 2021 Great Place to Work® in Canada for Second Consecutive Year

Company Earns Additional Certifications in Healthcare and Today’s Youth Categories TORONTO & DALLAS–(BUSINESS WIRE)–#award—Medchart is proud to announce that it has been certified as a 2021 Great Place to Work® Canada for the second year in a row after a thorough, independent analysis conducted by Great Place to Work Institute® Canada. Medchart also earned the … [Read more…]

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held virtually and in-person November 9-12, 2021 in Boston, MA. The poster presentation … [Read more…]

GC Labs Introduces the Microbiology Total Laboratory Automation System for the First Time in Korea

Improving efficiency and accuracy for microbiology tests YONGIN, South Korea–(BUSINESS WIRE)–GC Labs (CEO Eun-hee Lee), the leading clinical diagnostics company in Korea, announced on Oct. 12th that it has introduced WASPLab® (bioMerieux, France), the first microbiology Total Laboratory Automation system in Korea. When a sample arrives, a clinical microbiological lab receives the sample, and then … [Read more…]

Loulou Foundation Announces Launch of Pre-Competitive Industry Collaboration for CDKL5 Deficiency Disorder Observational Study

LONDON–(BUSINESS WIRE)–The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that seven biopharmaceutical industry partners together with the Loulou Foundation have formed a pre-competitive consortium to direct a key clinical study for the development of disease-modifying therapeutics for CDD. The seven companies … [Read more…]

Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021

New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including those with comorbidities previously excluded from clinical trials Analysis adds to the consistent body of efficacy and safety evidence for RBX2660 across prospective and retrospective analyses and varying patient populations PARSIPPANY, N.J.–(BUSINESS WIRE)–Ferring Pharmaceuticals and … [Read more…]

Fulgent Genetics to Announce Third Quarter 2021 Financial Results on Tuesday November 9, 2021

TEMPLE CITY, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2021 financial results after the market closes on Tuesday November 9, 2021. The company’s … [Read more…]

Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer

TROPION-Lung08 phase 3 trial to evaluate the Daiichi Sankyo and AstraZeneca TROP2 directed ADC with Merck & Co., Inc., Kenilworth, NJ., USA’s anti-PD-1 therapy as combination regimen for first-line metastatic NSCLC TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca (LSE/STO/Nasdaq: AZN) today announced that a second clinical … [Read more…]

Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

Company expands leadership team across business and science as it advances precision oncology pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)–Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Daphne Karydas as Chief Operating Officer and Chief Financial Officer, and Michaela Bowden, PhD, as Senior Vice … [Read more…]